BG105346A - Pyrolopyrimidines as protein kinase inhibitors - Google Patents
Pyrolopyrimidines as protein kinase inhibitorsInfo
- Publication number
- BG105346A BG105346A BG105346A BG10534601A BG105346A BG 105346 A BG105346 A BG 105346A BG 105346 A BG105346 A BG 105346A BG 10534601 A BG10534601 A BG 10534601A BG 105346 A BG105346 A BG 105346A
- Authority
- BG
- Bulgaria
- Prior art keywords
- compounds
- disorders
- pyrolopyrimidines
- protein kinase
- kinase inhibitors
- Prior art date
Links
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000003463 hyperproliferative effect Effects 0.000 abstract 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 abstract 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000002491 angiogenic effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Hematology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10083398P | 1998-09-18 | 1998-09-18 | |
| US10083298P | 1998-09-18 | 1998-09-18 | |
| US10094698P | 1998-09-18 | 1998-09-18 | |
| US10083498P | 1998-09-18 | 1998-09-18 | |
| PCT/US1999/021560 WO2000017203A1 (en) | 1998-09-18 | 1999-09-17 | Pyrrolopyrimidines as protein kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG105346A true BG105346A (en) | 2001-12-29 |
Family
ID=27493158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG105346A BG105346A (en) | 1998-09-18 | 2001-03-15 | Pyrolopyrimidines as protein kinase inhibitors |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1114053A1 (id) |
| JP (1) | JP2002526500A (id) |
| KR (1) | KR20010085824A (id) |
| CN (1) | CN1335849A (id) |
| AU (1) | AU753555C (id) |
| BG (1) | BG105346A (id) |
| BR (1) | BR9913887A (id) |
| CA (1) | CA2344249A1 (id) |
| CZ (1) | CZ2001960A3 (id) |
| HK (1) | HK1039326A1 (id) |
| HU (1) | HUP0200403A3 (id) |
| ID (1) | ID29028A (id) |
| IL (1) | IL141866A0 (id) |
| NO (1) | NO20011356L (id) |
| NZ (1) | NZ510588A (id) |
| PL (1) | PL346700A1 (id) |
| SK (1) | SK3842001A3 (id) |
| TR (1) | TR200101186T2 (id) |
| WO (1) | WO2000017203A1 (id) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| ES2274634T3 (es) | 1998-08-29 | 2007-05-16 | Astrazeneca Ab | Compuestos de pirimidina. |
| DE69932828T2 (de) | 1998-08-29 | 2007-10-18 | Astrazeneca Ab | Pyrimidine verbindungen |
| US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB9907658D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| EE05351B1 (et) | 1999-12-10 | 2010-10-15 | Pfizer Products Inc. | Prrolo[2,3-d]primidiinhendid |
| ES2293980T3 (es) * | 2000-01-13 | 2008-04-01 | Amgen Inc. | Agentes antibacterianos. |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004886D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
| WO2001072751A1 (en) * | 2000-03-29 | 2001-10-04 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
| US7369946B2 (en) | 2000-03-29 | 2008-05-06 | Abbott Gmbh & Co. Kg | Method of identifying inhibitors of Tie-2 |
| ATE423120T1 (de) | 2000-06-26 | 2009-03-15 | Pfizer Prod Inc | Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe |
| GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| US7081454B2 (en) | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
| TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
| GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
| GB0121033D0 (en) * | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| US7442697B2 (en) | 2002-03-09 | 2008-10-28 | Astrazeneca Ab | 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity |
| GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| AU2003246972A1 (en) | 2002-08-06 | 2004-02-23 | Astrazeneca Ab | Condensed pyridines and pyrimidines with tie2 (tek) activity |
| GB0226370D0 (en) * | 2002-11-12 | 2002-12-18 | Novartis Ag | Organic compounds |
| MXPA05005576A (es) | 2002-11-26 | 2005-07-27 | Pfizer Prod Inc | Procedimiento de tratamiento del rechazo a un trasplante. |
| UA80171C2 (en) | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
| PL378749A1 (pl) | 2003-03-12 | 2006-05-15 | Pfizer Products Inc. | Azabicykliczne pochodne pirydyloksymetylowe i benzoizoksazolowe |
| GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| AR045037A1 (es) | 2003-07-10 | 2005-10-12 | Aventis Pharma Sa | Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion. |
| US7312215B2 (en) | 2003-07-29 | 2007-12-25 | Bristol-Myers Squibb Company | Benzimidazole C-2 heterocycles as kinase inhibitors |
| US7338957B2 (en) * | 2003-08-28 | 2008-03-04 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| EP1687309A1 (en) * | 2003-11-17 | 2006-08-09 | Pfizer Products Inc. | Pyrrolopyrimidine compounds useful in treatment of cancer |
| CA2553724A1 (en) * | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
| TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
| UA89493C2 (uk) | 2004-04-02 | 2010-02-10 | Оси Фармасьютикалз, Инк. | 6,6-біциклічні кільцеві заміщені гетеробіциклічні інгібітори протеїнкіназ |
| EP1773836B1 (en) | 2004-05-27 | 2012-09-05 | Pfizer Products Inc. | Pyrrolopyrimidine derivatives useful in cancer treatment |
| TW200613306A (en) | 2004-07-20 | 2006-05-01 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
| PE20060748A1 (es) * | 2004-09-21 | 2006-10-01 | Smithkline Beecham Corp | Derivados de indolcarboxamida como inhibidores de quinasa ikk2 |
| RU2007138264A (ru) * | 2005-03-17 | 2009-09-10 | Новартис АГ (CH) | N-[3-(1-АМИНО-5,6,7,8-ТЕТРАГИДРО-2,4,4b-ТРИАЗАФЛУОРЕН-9-ИЛ)ФЕНИЛ]БЕНЗАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИН/ТРЕОНИНКИНАЗ, ПРЕЖДЕ ВСЕГО КИНАЗ В-RAF |
| CA2605738C (en) * | 2005-04-25 | 2013-10-01 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Novel azaheterocyclic compounds as kinase inhibitors |
| CA2623125A1 (en) | 2005-09-20 | 2007-03-29 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| EP1934213A1 (en) | 2005-09-30 | 2008-06-25 | Astra Zeneca AB | Imidazo [1,2-a] pyridine having anti-cell-proliferation activity |
| US8431695B2 (en) | 2005-11-02 | 2013-04-30 | Bayer Intellectual Property Gmbh | Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| AR057960A1 (es) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
| AU2007215161A1 (en) * | 2006-02-14 | 2007-08-23 | Vertex Pharmaceuticals Incorporated | Pyrrolo(3,2-C) pyridines useful as inhibitors of protein kinases |
| CN101490046A (zh) | 2006-05-09 | 2009-07-22 | 辉瑞产品公司 | 环烷基氨基酸衍生物及其药物组合物 |
| US8217177B2 (en) * | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| CN101808994B (zh) | 2007-07-17 | 2013-05-15 | 普莱希科公司 | 用于激酶调节的化合物和方法以及其适应症 |
| ES2467109T3 (es) | 2008-08-20 | 2014-06-11 | Zoetis Llc | Compuestos de pirrolo[2,3-d]pirimidina |
| AU2009305669A1 (en) * | 2008-10-16 | 2010-04-22 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
| MX2011004824A (es) | 2008-11-07 | 2012-01-12 | Triact Therapeutics Inc | Uso de derivados de butano catecólico en terapia contra el cáncer. |
| US20120016119A1 (en) * | 2009-01-22 | 2012-01-19 | Yasunori Tsuboi | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND |
| JP2012518657A (ja) | 2009-02-25 | 2012-08-16 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 併用抗癌治療 |
| US20110171124A1 (en) | 2009-02-26 | 2011-07-14 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the EMT status of tumor cells in vivo |
| JP2012519282A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
| WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| JP5656976B2 (ja) * | 2009-04-29 | 2015-01-21 | ローカス ファーマシューティカルズ インコーポレイテッド | ピロロトリアジン化合物 |
| US7741330B1 (en) * | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| AU2011223655A1 (en) | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| AU2011223643A1 (en) | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| US20130005733A1 (en) | 2010-03-09 | 2013-01-03 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
| WO2012120469A1 (en) * | 2011-03-08 | 2012-09-13 | Novartis Ag | Fluorophenyl bicyclic heteroaryl compounds |
| JP2014519813A (ja) | 2011-04-25 | 2014-08-21 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用 |
| MX2014000518A (es) | 2011-07-13 | 2014-05-30 | Pharmacyclics Inc | Inhibidores de la tirosina quinasa de bruton. |
| HUE041987T2 (hu) | 2011-07-19 | 2019-06-28 | Merck Sharp & Dohme | 4-Imidazopiridazin-1-il-benzamidok és 4-imidazotriazin-1-il-benzamidok mint BTK-gátlók |
| AU2012341028C1 (en) | 2011-09-02 | 2017-10-19 | Mount Sinai School Of Medicine | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| JP5985658B2 (ja) * | 2012-01-31 | 2016-09-06 | ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． | ブルトンチロシンキナーゼ阻害薬としての環状分子 |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| WO2014017659A1 (ja) | 2012-07-27 | 2014-01-30 | 独立行政法人理化学研究所 | 急性骨髄性白血病の治療又は再発抑制剤 |
| KR20150061651A (ko) | 2012-09-26 | 2015-06-04 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ire1의 조절 |
| JP6255038B2 (ja) | 2013-02-26 | 2017-12-27 | トリアクト セラピューティクス，インク． | 癌治療 |
| WO2015035410A1 (en) | 2013-09-09 | 2015-03-12 | Triact Therapeutic, Inc. | Cancer therapy |
| MA38961A1 (fr) | 2013-09-30 | 2018-05-31 | Pharmacyclics Llc | Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose |
| EP3067356B1 (en) * | 2013-11-08 | 2018-07-04 | ONO Pharmaceutical Co., Ltd. | Pyrrolo pyrimidine derivative |
| CA2833701A1 (en) * | 2013-11-19 | 2015-05-19 | Pharmascience Inc. | Protein kinase inhibitors |
| CA2834528A1 (en) * | 2013-11-26 | 2015-05-26 | Pharmascience Inc. | Protein kinase inhibitors |
| AP2016009297A0 (en) * | 2014-02-03 | 2016-06-30 | Cadila Healthcare Ltd | Novel heterocyclic compounds |
| US20170231986A1 (en) | 2014-08-11 | 2017-08-17 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor |
| US10112924B2 (en) | 2015-12-02 | 2018-10-30 | Astraea Therapeutics, Inc. | Piperdinyl nociceptin receptor compounds |
| KR20180094940A (ko) * | 2015-12-02 | 2018-08-24 | 아스트레아 테라퓨틱스 엘엘씨 | 피페리디닐 노시셉틴 수용체 화합물 |
| WO2020054788A1 (ja) | 2018-09-13 | 2020-03-19 | キッセイ薬品工業株式会社 | イミダゾピリジノン化合物 |
| WO2021038540A1 (en) | 2019-08-31 | 2021-03-04 | Sun Pharma Advanced Research Company Limited | Cycloalkylidene carboxylic acids and derivatives as btk inhibitors |
| JOP20220087A1 (ar) * | 2019-10-11 | 2023-01-30 | Incyte Corp | أمينات ثنائية الحلقة كمثبطات لـ cdk2 |
| CN112961159B (zh) * | 2020-03-05 | 2022-07-01 | 四川大学华西医院 | 氨基嘧啶并吡唑/吡咯类衍生物及其制备方法和用途 |
| CN112961158B (zh) * | 2020-03-05 | 2022-07-01 | 四川大学华西医院 | 氨基嘧啶并吡唑/吡咯类衍生物及其制备方法和用途 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| CN117402161A (zh) * | 2022-07-06 | 2024-01-16 | 上海科恩泰生物医药科技有限公司 | 一种具有fgfr抑制作用的亚砜亚胺类化合物、包含其的药物组合物及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3036390A1 (de) * | 1980-09-26 | 1982-05-13 | Troponwerke GmbH & Co KG, 5000 Köln | Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen |
| CA2100863A1 (en) * | 1991-01-23 | 1992-07-24 | David A. Bullough | Adenosine kinase inhibitors |
| IL108523A0 (en) * | 1993-02-03 | 1994-05-30 | Gensia Inc | Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain |
| CA2200210A1 (en) * | 1994-09-29 | 1996-04-04 | Novartis Ag | Pyrrolo[2,3-d]pyrimidines and their use |
| US6143749A (en) * | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| US5665721A (en) * | 1995-06-07 | 1997-09-09 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| CH690773A5 (de) * | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
| WO1997032879A1 (de) * | 1996-03-06 | 1997-09-12 | Novartis Ag | 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINE |
| CA2249739A1 (en) * | 1996-03-15 | 1997-09-25 | Novartis Ag | Novel n-7-heterocyclyl pyrrolo[2,3-d]pyridines and their use |
| AU748884B2 (en) * | 1997-03-19 | 2002-06-13 | Abbott Gmbh & Co. Kg | Pyrrolo(2,3d)pyrimidines and their use as tyrosine kinase inhibitors |
-
1999
- 1999-09-17 EP EP99969415A patent/EP1114053A1/en not_active Withdrawn
- 1999-09-17 HU HU0200403A patent/HUP0200403A3/hu unknown
- 1999-09-17 IL IL14186699A patent/IL141866A0/xx unknown
- 1999-09-17 TR TR2001/01186T patent/TR200101186T2/xx unknown
- 1999-09-17 KR KR1020017003532A patent/KR20010085824A/ko not_active Application Discontinuation
- 1999-09-17 CA CA002344249A patent/CA2344249A1/en not_active Abandoned
- 1999-09-17 ID IDW20010652A patent/ID29028A/id unknown
- 1999-09-17 CN CN99813217A patent/CN1335849A/zh active Pending
- 1999-09-17 AU AU60484/99A patent/AU753555C/en not_active Ceased
- 1999-09-17 BR BR9913887-5A patent/BR9913887A/pt not_active IP Right Cessation
- 1999-09-17 WO PCT/US1999/021560 patent/WO2000017203A1/en not_active Application Discontinuation
- 1999-09-17 SK SK384-2001A patent/SK3842001A3/sk unknown
- 1999-09-17 PL PL99346700A patent/PL346700A1/xx unknown
- 1999-09-17 CZ CZ2001960A patent/CZ2001960A3/cs unknown
- 1999-09-17 JP JP2000574112A patent/JP2002526500A/ja active Pending
- 1999-09-17 NZ NZ510588A patent/NZ510588A/en unknown
-
2001
- 2001-03-15 BG BG105346A patent/BG105346A/xx unknown
- 2001-03-16 NO NO20011356A patent/NO20011356L/no not_active Application Discontinuation
-
2002
- 2002-01-11 HK HK02100227.3A patent/HK1039326A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU753555B2 (en) | 2002-10-24 |
| CZ2001960A3 (cs) | 2001-10-17 |
| HK1039326A1 (zh) | 2002-04-19 |
| AU753555C (en) | 2003-07-03 |
| SK3842001A3 (en) | 2002-04-04 |
| AU6048499A (en) | 2000-04-10 |
| BR9913887A (pt) | 2001-10-23 |
| CA2344249A1 (en) | 2000-03-30 |
| NZ510588A (en) | 2003-08-29 |
| TR200101186T2 (tr) | 2001-10-22 |
| EP1114053A1 (en) | 2001-07-11 |
| IL141866A0 (en) | 2002-03-10 |
| NO20011356D0 (no) | 2001-03-16 |
| NO20011356L (no) | 2001-05-16 |
| ID29028A (id) | 2001-07-26 |
| KR20010085824A (ko) | 2001-09-07 |
| HUP0200403A3 (en) | 2004-07-28 |
| JP2002526500A (ja) | 2002-08-20 |
| PL346700A1 (en) | 2002-02-25 |
| WO2000017203A1 (en) | 2000-03-30 |
| CN1335849A (zh) | 2002-02-13 |
| HUP0200403A2 (en) | 2002-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG105346A (en) | Pyrolopyrimidines as protein kinase inhibitors | |
| PL347138A1 (en) | 4-aminopyrrolopyrimidines as kinase inhibitors | |
| TR200102001T2 (tr) | P38 kinaz inhibitörleri olarak sübstitüe edilmiş pirazoller | |
| TR199900048T2 (xx) | Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler | |
| BG104597A (en) | Inhibition of raf kinase using substituted heterocyclic ureas | |
| BG104598A (en) | Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas | |
| DE59710417D1 (de) | N-7 HETEROCYCLYL-PYRROLO[ 2,3-d]PYRIMIDINE UND IHRE VERWENDUNG | |
| ATE281451T1 (de) | Imidazolderivate und deren verwendung als raf kinase inhibitoren | |
| EE03770B1 (et) | Pürido[2,3-d]pürimidiinid kui türosiinkinaas-valgu poolt vahendatava rakkude proliferatsiooni inhibiitorid, farmatseutiline kompositsioon, kasutamine | |
| ATE324877T1 (de) | Behandlung von metastatischer krankheit | |
| AP2001002318A0 (en) | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | |
| NO970162L (no) | Substituerte pyrimidinforbindelser og anvendelse derav | |
| NO20020487L (no) | 2-Pyrazolin-5-oner | |
| MX9605915A (es) | Derivados de piperazina como antagonistas de 5ht1a. | |
| TR200000014T2 (tr) | Yeni ikameli imidazol bileşimleri. | |
| ES2000734A6 (es) | Un procedimiento para la preparacion de pirimidinas | |
| ES2121993T3 (es) | Derivados de 4-oxo-2-tioxoimidazolidina como sustancias inhibidoras de la agregacion de plaquetas sanguineas. | |
| EP1233951A4 (en) | 3,4-DIHYDRO (1H) CHINAZOLIN-2-ON COMPOUNDS AS CSBP / P38 KINASE INHIBITORS | |
| ES2001782A6 (es) | Un procedimiento para preparar derivados de bencimidazol | |
| ES2249309T3 (es) | Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa. | |
| ATE390137T1 (de) | Verwendung von pyridin-2,4-dicarbons urediamiden und pyrimid in-4,6-dicarbons urediamiden zur selektiven inhibierung von kollagenasen | |
| ATE281439T1 (de) | 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren | |
| BG105355A (en) | 4-aminopyrrolopyrimidines as kinase inhibitors | |
| ATE67992T1 (de) | In 4-stellung durch stickstoff substituierte isochinolinolverbindungen mit cardiotonischen, die wirkung von phosphodiesterase-fraktion-iii inhibierenden und/oder renal vasodilatierenden eigenschaften. | |
| ATE239721T1 (de) | Zimtsäure-derivate als zelladhäsions-moleküle |